Status:
ACTIVE_NOT_RECRUITING
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
Lead Sponsor:
Institut Paoli-Calmettes
Conditions:
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study aims at evaluating the safety of an approach based on HLA-mismatched Microtransplantation without immunosuppressive treatment in patients With myeloid hemopathies who are ineligible to conv...
Eligibility Criteria
Inclusion
- Age\> or = 65 years with a myeloid hemopathy in Complete Remission or Complete remission with incomplete hematological recovery or Age\<65 years with an ineligibility to allograft (contraindication to conditioning)
- HLA-partially matched family donors
- Affiliated to(or beneficiary of) the Social Security
- Informed consent signed
Exclusion
- AML3
- Previous Hematopoietic Stem Cell TRansplantation
- Uncontrolled infection -PS\>3 -Other progressive cancer
- Psychiatric disease
- Vulnerable person or unable to provide informed consent
- Emergency
- Unable to comply with required study follow up
Key Trial Info
Start Date :
March 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 9 2027
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03232268
Start Date
March 9 2018
End Date
March 9 2027
Last Update
June 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Paoli Calmettes
Marseille, Bouches du Rhône, France, 13009